<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-05-18T14:50:53Z</responseDate><request verb="GetRecord" identifier="oai:uvadoc.uva.es:10324/55602" metadataPrefix="oai_dc">https://uvadoc.uva.es/oai/request</request><GetRecord><record><header><identifier>oai:uvadoc.uva.es:10324/55602</identifier><datestamp>2025-02-13T10:09:32Z</datestamp><setSpec>com_10324_40357</setSpec><setSpec>com_10324_952</setSpec><setSpec>com_10324_894</setSpec><setSpec>col_10324_40358</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
<dc:title>Olive pomace phenolic compounds: from an agro-industrial by-product to a promising ocular surface protection for dry eye disease</dc:title>
<dc:creator>Katsinas, Nicolaos</dc:creator>
<dc:creator>Gehlsen, Uta</dc:creator>
<dc:creator>García Posadas, Laura</dc:creator>
<dc:creator>Rodríguez Rojo, Soraya</dc:creator>
<dc:creator>Steven, Philipp</dc:creator>
<dc:creator>González García, María Jesús</dc:creator>
<dc:creator>Enriquez De Salamanca Aladro, Amalia</dc:creator>
<dc:subject>Ojo - Enfermedades y defectos - Tratamiento</dc:subject>
<dc:subject>Síndrome de ojo seco</dc:subject>
<dc:subject>Aceite de oliva</dc:subject>
<dc:subject>Aceite de oliva - Análisis</dc:subject>
<dc:subject>Olive pomace</dc:subject>
<dc:subject>Phenolic extracts</dc:subject>
<dc:subject>3201.09 Oftalmología</dc:subject>
<dc:description>Producción Científica</dc:description>
<dc:description>Dry eye (DED) is a prevalent disease with immune-mediated inflammation as the principal pathophysiological etiology. Olive pomace, the major by-product of the olive oil industry, is rich in high-value polyphenols. Their anti-inflammatory and immunomodulatory activities were determined on human CD4+ T cells (hTCD4+) and in a DED animal model. The viability of hTCD4+ cells isolated from peripheral blood and activated with phytohemagglutinin-M was evaluated after treatment for 48 h with an olive pomace extract (OPT3, 0.10–0.40 mg/mL) and its major compound, hydroxytyrosol (25–100 μM). Regarding the DED animal model, 100 μM hydroxytyrosol, 0.20 mg/mL OPT3, or vehicle (borate buffer) were topically administered to 14 days-desiccating stress-exposed (constant airflow/scopolamine administration) C57BL/6 mice. Tear volume, corneal fluorescein staining (CFS), CD4+, and CD8+ T cell count in lymph nodes (flow cytometry), and IP-10 and TNF-α gene expression (qRT-PCR) in the cornea, conjunctiva, and lacrimal glands were evaluated. OPT3 (0.2–0.4 mg/mL) and hydroxytyrosol (100 μM) significantly reduced hTCD4+ proliferation. In mice, both treatments reduced lacrimal gland IP-10 gene expression. OPT3 also decreased CFS, and conjunctival IP-10 and corneal TNF-α gene expression. In lymph nodes, hydroxytyrosol reduced CD3+, OPT3, and CD8+ count. Thus, a high-value application as a promising DED protection was proposed for olive pomace.</dc:description>
<dc:description>European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Initial Training Network (ITN) “IT-DED3” (H2020-MSCA-ITN-2017) - (grant 765608)</dc:description>
<dc:description>Ministerio de Ciencia e Innovación y Fondo Europeo de Desarrollo Regional (FEDER) (RTI2018-094071-B-C21)</dc:description>
<dc:date>2022-09-23T08:07:58Z</dc:date>
<dc:date>2022-09-23T08:07:58Z</dc:date>
<dc:date>2022</dc:date>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
<dc:identifier>https://doi.org/10.3390/jcm11164703</dc:identifier>
<dc:identifier>Journal of Clinical Medicine, 2022, Vol. 11, Nº. 16, 17 pp.</dc:identifier>
<dc:identifier>2077-0383</dc:identifier>
<dc:identifier>https://uvadoc.uva.es/handle/10324/55602</dc:identifier>
<dc:identifier>1</dc:identifier>
<dc:identifier>16</dc:identifier>
<dc:identifier>17</dc:identifier>
<dc:identifier>Journal of Clinical Medicine</dc:identifier>
<dc:identifier>11</dc:identifier>
<dc:identifier>2077-0383</dc:identifier>
<dc:language>eng</dc:language>
<dc:relation>https://www.mdpi.com/2077-0383/11/16/4703</dc:relation>
<dc:relation>info:eu-repo/grantAgreement/EC/H2020/765608</dc:relation>
<dc:rights>Atribución 4.0 Internacional</dc:rights>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
<dc:rights>© 2022 The Authors</dc:rights>
<dc:format>application/pdf</dc:format>
<dc:publisher>MDPI</dc:publisher>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>